Aileron Therapeutics Secures $33 Million in Financing, Expands Senior Management Team
Aileron Therapeutics, a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, has secured $33 million in an extension to its Series E equity financing, bringing the total raised in this round to $48 million.
This financing was co-led by three new investors including AJU IB Investment Co., Ltd. and two undisclosed private investment groups. The round also includes full participation by all existing investors including Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund and SR One.
The proceeds will be used to advance ALRN-6924 into clinical trials. ALRN-6924 is a potent and specific re-activator of p53, a tumour suppressor protein that represents one of the most sought after oncology drug targets given its role in most liquid and solid tumours. ALRN-6924 will be the first clinical drug candidate that targets both the MDM2 and the MDMX suppressor proteins of p53, in contrast to all other drugs in clinical development that involve small molecules targeting only MDM2.
“This financing enables Aileron to rapidly move forward the clinical development of ALRN-6924 as well as ongoing translational research. P53 is one of the most exciting and valuable oncology targets given its potential to impact a very broad range of cancers and patients,” said Joseph A. Yanchik III, President and CEO of Aileron Therapeutics. “This investment from our new and returning investors recognises the progress and value that the Aileron team has created and gives us a strong foundation to accelerate the growth of this very important oncology drug as well as our unique drug platform.”
“We are very pleased with Aileron’s progress and look forward to advancing the first Stapled Peptide drug for oncology into the clinic,” said Scott Kapnick, Chairman of Aileron’s Board of Directors. “We are grateful to have the full and continued participation of our existing investors. The high quality of the new investment groups that participated in this financing reflects the importance of this research to cancer treatment.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance